When librarians troll

5a7aa77523233_8f3adkgrsfe01__700

Advertisements

Net Neutrality

Network neutrality protections were approved by the Federal Communications Commission (FCC) in 2015 and affirmed by the federal appeals court in 2016. The Medical Library Association (MLA) and the Association of Academic Health Sciences Libraries (AAHSL) support net neutrality. Revoking net neutrality protections would mean that broadband businesses would no longer face regulation under Title II of the Communications Act, opening the door for anti-consumer practices such as paid prioritization for applications and services. Instead of recognizing that unfettered Internet access has become essential to modern life, providers could charge more for access, slow down access, for instance, in rural or intercity areas, or offer preferential treatment to certain content.

Why net neutrality matters:

  • Health sciences libraries require an open internet to provide
    • unencumbered access to the National Library of Medicine’s (NLM) almost 300 databases that support health care, education, and research; and
    • Internet access to images that support telemedicine. Health-E-Access at the University of Rochester, for example, connects underserved children to telehealth opportunities via broadband internet access. It has enabled access to experts for more than 10,000 child visits.
  • The public requires Internet access without restriction and barriers to access health information. As an example, 65,000 people access ClinicalTrials.gov daily. And PubMed Central provided access to more than 4.2 million biomedical full-text articles.

A vote is set for December 14th unless strong disapproval from Congress forces a pause in the vote. To leave a comment for the FCC on Proceeding #17-108 go to www.fcc.gov/ecfs/filings/express

Ten highly cited NJH papers from 2017

Indexed in Web of Science (October 2017)

Dransfield MT, Kunisaki KM, Strand MJ, Anzueto A, Bhatt SP, Bowler RP, et al. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2017;195(3):324-30.

El Agha E, Moiseenko A, Kheirollahi V, De Langhe S, Crnkovic S, Kwapiszewska G, et al. Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. Cell Stem Cell. 2017;20(2):261-+.

Jones SM, Sicherer SH, Burks AW, Leung DYM, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. Journal of Allergy and Clinical Immunology. 2017;139(4):1242-+.

Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, et al. Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. American Journal of Respiratory and Critical Care Medicine. 2017;195(4):473-81.

Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases. 2017;64(2):111-5.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine. 2017;5(1):33-41.

Nolte H, Casale TB, Lockey RF, Fogh BS, Kaur A, Lu S, et al. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. Journal of Allergy and Clinical Immunology-in Practice. 2017;5(1):84-+.

Olivier KN, Griffith DE, Eagle G, McGinnis JP, Micioni L, Liu K, et al. Randomized Trial of Liposomal Amikacin for Inhlation in Nontuberculous Mycobacterial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2017;195(6):814-23.

Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine. 2017;5(1):22-32.

Stray-Pedersen A, Sorte HS, Samarakoon P, Gambin T, Chinn IK, Akdemir ZHC, et al. Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. Journal of Allergy and Clinical Immunology. 2017;139(1):232-45.